Pay in 4 interest-free payments of $6.71 Learn more
Ships within 48 hours · Estimated delivery Sep 1 - Sep 6
Metabolism 2010;59:123-133
RGN-352 was shown to be safe and well-tolerated with no serious drug-related adverse events reported (PMID: 20536472) Phase 2 AMI trial (incomplete): RegeneRx designed a Phase 2 proof-of-concept trial (NCT01311518) to evaluate RGN-352 in approximately 75 patients with acute ST-segment elevation myocardial infarction (heart attack)
546,547 Olpasiran demonstrated a dose-dependent reduction in Lp(a) levels, with a single dose of 9 mg or higher reducing Lp(a) concentrations by over 90% for several months (NCT03626662)
But there are savings options that can help bring down the out-of-pocket cost
If you choose the injection, you give yourself a shot once a week with a prefilled pen in the skin of your abdomen, thigh, or upper arm
US$ 27.39
US$ 20.83
US$ 28.95
US$ 28.74
US$ 28.18
US$ 26.68
US$ 23.57
US$ 23.11
US$ 23.57
US$ 23.86
